24-hour intraocular pressures with brimonidine purite versus dorzolamide added to latanoprost in primary open-angle glaucoma subjects.

Abstract

OBJECTIVE:

To evaluate the 24-hour efficacy of brimonidine purite versus dorzolamide, each added to latanoprost.

DESIGN:

Double-masked, 2-center, prospective, crossover comparison.

PARTICIPANTS:

Primary open-angle glaucoma (POAG) subjects.

METHODS:

Subjects were randomized to brimonidine purite or dorzolamide, each given twice daily, for the first 6-week treatment period after a 6-week latanoprost run-in. Subjects began the opposite treatment for the second 6-week period after a 6-week latanoprost-only treatment between periods. Intraocular pressure (IOP) was measured at 8 am, 12 pm, 4 pm, 8 pm, 12 am, 4 am, and 8 am at each baseline and at the end of each treatment period. This study provided an 80% power that a 1.5-mmHg difference could be excluded between groups if 27 subjects completed the study. A standard deviation (SD) of 2.8 mmHg was assumed.

MAIN OUTCOME MEASURES:

Twenty-four-hour efficacy of intraocular pressures of brimonidine purite versus dorzolamide, each added to latanoprost.

RESULTS:

In 31 completed subjects, the baseline mean diurnal 24-hour IOP (+/- SD) was 19.0+/-1.7 mmHg for brimonidine purite and 19.0+/-1.6 mmHg for dorzolamide (P = 0.52). The 8 am IOP after 6 weeks of therapy was 18.4+/-2.1 mmHg for brimonidine purite and 18.9+/-1.9 mmHg for dorzolamide (P = 0.40). The mean diurnal IOP was 16.9+/-1.5 mmHg for brimonidine purite and 16.8+/-1.5 mmHg for dorzolamide (P = 0.66). Dorzolamide caused a more bitter taste (P = 0.01) than brimonidine purite.

CONCLUSIONS:

This study suggests that brimonidine purite and dorzolamide, added to latanoprost, have similar efficacy and safety in POAG or ocular hypertensive subjects.

• Authors: Anastasios G P Konstas, Costas H Karabatsas, Nikolaos Lallos, Nikolaos Georgiadis, Aikaterini Kotsimpou, Jeanette A Stewart, William C Stewart
• Journal: Ophthalmology (Ophthalmology) Vol. 112 Issue 4 Pg. 603-8 (Apr 2005) ISSN: 1549-4713 [Electronic] United States
• PMID: 15808251 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)

Chemical References

• Antihypertensive Agents
• Prostaglandins F, Synthetic
• Quinoxalines
• Sulfonamides
• Thiophenes
• Brimonidine Tartrate
• Latanoprost
• dorzolamide

Topics

• Aged
• Antihypertensive Agents (adverse effects, therapeutic use)
• Brimonidine Tartrate
• Circadian Rhythm
• Cross-Over Studies
• Double-Blind Method
• Drug Therapy, Combination
• Female
• Glaucoma, Open-Angle (drug therapy)
• Humans
• Intraocular Pressure (drug effects)
• Latanoprost
• Male
• Prospective Studies
• Prostaglandins F, Synthetic (adverse effects, therapeutic use)
• Quinoxalines (adverse effects, therapeutic use)
• Safety
• Sulfonamides (adverse effects, therapeutic use)
• Thiophenes (adverse effects, therapeutic use)
• Visual Acuity